AGM/EGMJun 2, 2026, 04:32 PM
Kyverna Stockholders Elect Directors, Ratify Auditor at Annual Meeting
AI Summary
Kyverna Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on May 27, 2026, with approximately 73% of outstanding shares represented, constituting a quorum. Stockholders voted to elect Ian Clark and Christi Shaw as Class II directors, who will serve until the 2029 annual meeting. Additionally, the appointment of BDO USA, P.C. as the independent registered public accounting firm for the year ending December 31, 2026, was ratified.
Key Highlights
- Kyverna Therapeutics held its 2026 Annual Meeting of Stockholders on May 27, 2026.
- A quorum was met with 43,987,007 shares represented, approximately 73% of outstanding shares.
- Ian Clark was elected as a Class II director with 31,505,902 votes for.
- Christi Shaw was elected as a Class II director with 34,528,865 votes for.
- Both elected directors will serve until the Company's 2029 annual meeting.
- Stockholders ratified BDO USA, P.C. as the independent auditor for 2026 with 43,830,300 votes for.
Price Impact
More from KYTX